Literature DB >> 7927313

Expression of p53, transforming growth factor alpha, epidermal growth factor receptor, and c-erbB-2 in endometrial carcinoma and correlation with survival and known predictors of survival.

J J Reinartz1, E George, B R Lindgren, G A Niehans.   

Abstract

Abnormal expression of p53, transforming growth factor alpha (TGF alpha), epidermal growth factor receptor (EGFR), and c-erbB-2 occurs in a variety of cancers and in some cases is associated with poor prognosis. Immunoperoxidase staining using these markers in formalin-fixed, paraffin-embedded endometrial carcinoma tissue was performed to determine whether immunoreactivity correlates with survival and known prognostic variables. Cases included 84 endometrioid adenocarcinomas, five adenoacanthomas, 12 adenosquamous carcinomas, 11 serous carcinomas, 15 clear cell carcinomas, and one carcinosarcoma for a total of 128 cases. Frequencies of immunoreactivity were as follows: p53, 37 of 128 (29%); TGF alpha, strong (2+) 23 of 128 (18%) and intermediate (1+) 26 of 128 (20%); EGFR, strong (3+) 21 of 128 (16%) and intermediate (2+ or 1+) 83 of 128 (65%); and c-erbB-2, strong (2+) four of 128 (2%) and intermediate (1+) three of 128 (1%). p53 and TGF alpha staining showed statistically significant correlations with decreased length of survival (P < .0017 and P < .0013, respectively, generalized Savage [Mantel Cox]). p53 immunoreactivity correlated with tumor types, grade, and stage. Transforming growth factor alpha staining correlated with increased depth of invasion and presence of vascular invasion. Epidermal growth factor receptor staining did not correlate with length of survival or known prognostic variables. c-erbB-2 staining correlated with tumor type. In the multivariate analysis p53 and TGF alpha staining were not independent predictors of survival when other variables were taken into account, including grade, stage, tumor type, presence of vascular invasion, and depth of invasion. Grade and stage were the only independent predictors of survival when used in combination in a Cox proportional hazards model.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7927313     DOI: 10.1016/0046-8177(94)90068-x

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  13 in total

1.  A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: a Gynecologic Oncology Group study.

Authors:  Kimberly K Leslie; Michael W Sill; Edgar Fischer; Kathleen M Darcy; Robert S Mannel; Krishnansu S Tewari; Parviz Hanjani; Jason A Wilken; Andre T Baron; Andrew K Godwin; Russell J Schilder; Meenakshi Singh; Nita J Maihle
Journal:  Gynecol Oncol       Date:  2013-02-21       Impact factor: 5.482

2.  Expression of TGFalpha in meningiomas.

Authors:  J Halper; C Jung; A Perry; H Suliman; M P Hill; B Scheithauer
Journal:  J Neurooncol       Date:  1999       Impact factor: 4.130

3.  Epidermal growth factor receptor is a critical mediator of ultraviolet B irradiation-induced signal transduction in immortalized human keratinocyte HaCaT cells.

Authors:  Yiru Xu; John J Voorhees; Gary J Fisher
Journal:  Am J Pathol       Date:  2006-09       Impact factor: 4.307

4.  Insights into endometrial serous carcinogenesis and progression.

Authors:  Oluwole Fadare; Wenxin Zheng
Journal:  Int J Clin Exp Pathol       Date:  2009-01-10

Review 5.  Promising novel therapies for the treatment of endometrial cancer.

Authors:  Paola A Gehrig; Victoria L Bae-Jump
Journal:  Gynecol Oncol       Date:  2009-11-10       Impact factor: 5.482

6.  Apoptosis and Expression of the Proto-Oncogenes bcl-2 and p53 and the Proliferation Factor Ki-67 in Human Medullary Thyroid Carcinoma.

Authors:  Wenliang Wang; Henry Johansson; Ulla Bergholm; Erik Wilander; Lars Grimelius
Journal:  Endocr Pathol       Date:  1996       Impact factor: 3.943

7.  The effect of cell type on surgico-pathologic risk factors in endometrial cancer.

Authors:  Ahmet Taner Turan; Betül Dündar; Burcu Gündoğdu; Abdullah Boztosun; Nejat Ozgül; Nurettin Boran; Gökhan Tulunay; Ahmet Ozfuttu; Mehmet Faruk Köse
Journal:  J Turk Ger Gynecol Assoc       Date:  2011-03-01

Review 8.  The clinical significance of p53 aberrations in human tumours.

Authors:  S Bosari; G Viale
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

9.  Independent prognostic importance of microvessel density in endometrial carcinoma.

Authors:  H B Salvesen; O E Iversen; L A Akslen
Journal:  Br J Cancer       Date:  1998-04       Impact factor: 7.640

10.  HER2 gene amplification and EGFR expression in a large cohort of surgically staged patients with nonendometrioid (type II) endometrial cancer.

Authors:  G E Konecny; L Santos; B Winterhoff; M Hatmal; G L Keeney; A Mariani; M Jones; C Neuper; B Thomas; L Muderspach; D Riehle; H-J Wang; S Dowdy; K C Podratz; M F Press
Journal:  Br J Cancer       Date:  2008-12-16       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.